- Previous Close
14.09 - Open
13.18 - Bid 10.80 x 100
- Ask 15.11 x 200
- Day's Range
11.36 - 15.08 - 52 Week Range
11.36 - 6,241.05 - Volume
146,835 - Avg. Volume
208,014 - Market Cap (intraday)
6.157M - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
-- - EPS (TTM)
-5,658.42 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11,758.41
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN software application, a non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also develops NOCISCAN Post-Processor Suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
www.aclarion.com4
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ACON
View MorePerformance Overview: ACON
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACON
View MoreValuation Measures
Market Cap
6.16M
Enterprise Value
5.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.27
Price/Book (mrq)
2.45
Enterprise Value/Revenue
116.89
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-127.69%
Return on Equity (ttm)
-745.47%
Revenue (ttm)
49.29k
Net Income Avi to Common (ttm)
-6.28M
Diluted EPS (ttm)
-5,658.42
Balance Sheet and Cash Flow
Total Cash (mrq)
1.36M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.84M